Antiplatelet Therapy for Percutaneous Coronary Intervention: Something Old and Something New

被引：0
作者：
Gaglia M.A., Jr. [1 ]
机构：
[1] Division of Cardiology, University of New Mexico School of Medicine, 1 University of New Mexico, MSC 10-5550, Albuquerque, 87131, NM
来源：
Current Cardiovascular Risk Reports | 2017年 / 11卷 / 3期
关键词：
Aspirin; Cangrelor; Clopidogrel; Percutaneous coronary intervention; Platelet aggregation inhibitors; Prasugrel; Ticagrelor;
D O I：
10.1007/s12170-017-0533-x
中图分类号：
学科分类号：
摘要：
Purpose of Review: Antiplatelet therapy for patients undergoing percutaneous coronary intervention has rapidly evolved over the last 10 years, often outpacing clinical guidelines. This review appraises recent clinical trials within the context of landmark trials in interventional cardiology, and offers a framework for the integration of recent trials into clinical practice. Recent Findings: This review interprets recent evidence regarding the following: (1) aspirin and the most effective dose; (2) the role of the newer, more potent P2Y12 inhibitors prasugrel, ticagrelor, and cangrelor; (3) an appraisal of the evolving paradigm for duration of dual antiplatelet therapy; and (4) perspective on the role of glycoprotein IIb/IIIa inhibitors in the era of routine and potent P2Y12 inhibition. Summary: The newer and more potent P2Y12 inhibitors, as well as a more nuanced understanding of mainstays of treatment like aspirin, offer the promise of maximizing ischemic benefit and minimizing bleeding in patients undergoing percutaneous coronary intervention. © 2017, Springer Science+Business Media New York.
引用
收藏
相关论文
共 53 条
  • [1] Eikelboom J.W., Hirsh J., Spencer F.A., Baglin T.P., Weitz J.I., Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, 141, pp. e89S-eS119, (2012)
  • [2] Cipollone F., Patrignani P., Greco A., Panara M.R., Padovano R., Cuccurullo F., Et al., Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina, Circulation, 96, 4, pp. 1109-1116, (1997)
  • [3] Patrono C., Garcia Rodriguez L.A., Landolfi R., Baigent C., Low-dose aspirin for the prevention of atherothrombosis, N Engl J Med, 353, 22, pp. 2373-2383, (2005)
  • [4] Grosser T., Fries S., FitzGerald G.A., Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities, J Clin Invest, 116, 1, pp. 4-15, (2006)
  • [5] Garcia Rodriguez L.A., Hernandez-Diaz S., de Abajo F.J., Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies, Br J Clin Pharmacol, 52, 5, pp. 563-571, (2001)
  • [6] Roderick P.J., Wilkes H.C., Meade T.W., The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials, Br J Clin Pharmacol, 35, 3, pp. 219-226, (1993)
  • [7] Jolly S.S., Pogue J., Haladyn K., Peters R.J., Fox K.A., Avezum A., Et al., Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study, Eur Heart J, 30, 8, pp. 900-907, (2009)
  • [8] Xian Y., Wang T.Y., McCoy L.A., Effron M.B., Henry T.D., Bach R.G., Et al., Association of discharge aspirin dose with outcomes after acute myocardial infarction: insights from the treatment with ADP receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study, Circulation, 132, 3, pp. 174-181, (2015)
  • [9] Mahaffey K.W., Wojdyla D.M., Carroll K., Becker R.C., Storey R.F., Angiolillo D.J., Et al., Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial, Circulation, 124, 5, pp. 544-554, (2011)
  • [10] Mehta S.R., Tanguay J.F., Eikelboom J.W., Jolly S.S., Joyner C.D., Granger C.B., Et al., Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial, Lancet, 376, 9748, pp. 1233-1243, (2010)
123456